Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel therapeutic approaches in chronic myeloid leukemia
Nurgül Özgür Yurttaş, Ahmet Emre Eşkazan
Leukemia Research (2020) Vol. 91, pp. 106337-106337
Closed Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Third-line therapy for chronic myeloid leukemia: current status and future directions
Jorge E. Cortés, Fabian Lang
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 93
Chronic myeloid leukemia stem cells: targeting therapeutic implications
Hanieh Mojtahedi, Niloufar Yazdanpanah, Nima Rezaei
Stem Cell Research & Therapy (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 51
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities
Zehra Narlı Özdemir, Necati Alp Kılıçaslan, Musa Yılmaz, et al.
International Journal of Hematology (2022) Vol. 117, Iss. 1, pp. 3-15
Open Access | Times Cited: 31
Global, regional, and national burdens of leukemia from 1990 to 2017: a systematic analysis of the global burden of disease 2017 study
Xiangjie Lin, Jinghan Wang, Xin Huang, et al.
Aging (2021) Vol. 13, Iss. 7, pp. 10468-10489
Open Access | Times Cited: 39
HDAC inhibitors: Promising agents for leukemia treatment
Yun Deng, Cheng Qian, Jing He
Biochemical and Biophysical Research Communications (2023) Vol. 680, pp. 61-72
Closed Access | Times Cited: 11
Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy
Emanuela Andretta, Caterina Costa, Consiglia Longobardi, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 24
WITHDRAWN: Agaricus blazei extract FA2bβ enhances the sensitivity of K562/ADR cells through the PI3K/Akt/mTOR signalling pathway
dongping wang, Wanwen Ge, Yanqing Sun
Research Square (Research Square) (2025)
Closed Access
Structure and Dynamics of the ABL1 Tyrosine Kinase and Its Important Role in Chronic Myeloid Leukemia
Ayca Irgit, Reyhan Kamıs, Belgin Sever, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 5
Open Access
External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia
Álvaro Corral Alaejos, Aránzazu Zarzuelo Castañeda, Silvia Jiménez, et al.
British Journal of Clinical Pharmacology (2021) Vol. 88, Iss. 4, pp. 1913-1924
Open Access | Times Cited: 19
Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Sara Malik, Shahzeb Hassan, Ahmet Emre Eşkazan
Expert Review of Hematology (2021) Vol. 14, Iss. 11, pp. 975-978
Open Access | Times Cited: 17
A Review on the Therapeutic Role of TKIs in Case of CML in Combination With Epigenetic Drugs
Mohd Amir, Saleem Javed
Frontiers in Genetics (2021) Vol. 12
Open Access | Times Cited: 17
Chronic myeloid leukemia: cytogenetics and molecular biology’s part in the comprehension and management of the pathology and treatment evolution
Sara Benchikh, Amale Bousfiha, Adil El Hamouchi, et al.
Egyptian Journal of Medical Human Genetics (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 12
CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?
Ariadna Bartoló‐Ibars, Mireia Uribe‐Herranz, Guillermo Muñoz‐Sánchez, et al.
Cancers (2021) Vol. 13, Iss. 18, pp. 4664-4664
Open Access | Times Cited: 16
I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition
Congying Gao, Lei Zhang, Yun Xu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
Yammy Yung, Emily Lee, Hiutung Chu, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 659-659
Open Access | Times Cited: 12
Sphagneticola Trilobata (L.) Pruski (Asteraceae) Methanol Extract Induces Apoptosis in Leukemia Cells through Suppression of BCR/ABL
Hoàng Thanh, Nguyen Thi Lien Thuong, Bùi Thị Kim Lý
Plants (2021) Vol. 10, Iss. 5, pp. 980-980
Open Access | Times Cited: 11
Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review
Mohammad Al Hamad
F1000Research (2021) Vol. 10, pp. 1288-1288
Open Access | Times Cited: 11
Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review
Mohammad Al Hamad
F1000Research (2022) Vol. 10, pp. 1288-1288
Open Access | Times Cited: 7
Semisynthetic phytochemicals in cancer treatment: a medicinal chemistry perspective
Meghna Arora, Ankit Kumar Singh, Adarsh Kumar, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 10, pp. 3345-3370
Closed Access | Times Cited: 1
Asciminib as a new option in the treatment of chronic myeloid leukemia
Betül İbiş, Mario Tiribelli, Ahmet Emre Eşkazan
Future Oncology (2021) Vol. 17, Iss. 36, pp. 5003-5005
Closed Access | Times Cited: 9
Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells
Ondřej Mitrovský, Denisa Myslivcová, Tereza Macháčková-Lopotová, et al.
PLoS ONE (2023) Vol. 18, Iss. 5, pp. e0284876-e0284876
Open Access | Times Cited: 3
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
Manuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 5
Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia
Massimo Breccia, Elisabetta Abruzzese, Mario Annunziata, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 6
Asciminib in chronic myeloid leukemia: many questions still remain to be answered
Ahmet Emre Eşkazan
Blood Cancer Journal (2021) Vol. 11, Iss. 4
Open Access | Times Cited: 6
Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review
Umut Yılmaz, Batuhan Bulan, Çağrı Belli, et al.
Expert Review of Hematology (2022) Vol. 15, Iss. 5, pp. 423-429
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top